Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-COPD triple therapy prevention trial
ACTRN12625000663459Phase 3Not yet recruiting
- Sponsor
- University of Melbourne
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University of Melbourne. Primary endpoint: Change in post-bronchodilator forced expiratory volume in 1 second. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12625000663459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000663459.